Lupin has launched its generic version of Tobi inhalation solution in the US, the company said. The FDA granted final approval of Lupin’s ANDA for its tobramycin inhalation inhalation solution in March 2017.
The 300 mg/5 ml inhalation solution is indicated for the treatment of P. aeruginosa lung infections in cystic fibrosis patients.
Read the Lupin press release.
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
